The European Medicines Agency (EMA) said on Monday it would no longer post on X and would use rival Bluesky instead, becoming ...

This delay, attributed to procedural issues at the European Medicines Agency (EMA), has implications for the review process of lecanemab, a pivotal drug currently under EMA evaluation. Also Read ...

The two products, both manufactured by Amgen, are aflibercept biosimilars Pavblu and Skojoy. Both biosimilars are indicated ...

The European Medicines Agency (EMA) announced on Monday that it will be discontinuing its presence on X, opting instead to utilize rival platform Bluesky.

A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.

Although the perceived risk is likely to affect the choice of evaluation approach ... on the other hand. European Medicines Agency. Guideline on Immunogenicity Assessment of Biotechnology-derived ...

EMA is a decentralised agency of the European Union, responsible for the scientific evaluation, supervision and safety monitoring of medicines. Its headquarters is in Amsterdam, the Netherlands.

AMSTERDAM (Reuters) - The European Medicines Agency (EMA) said on Monday it would ... responsible for the scientific evaluation, supervision and safety monitoring of medicines.